What is the 13F Pro Quality Score for TKNO?

13F Pro ranks Alpha Teknova, Inc. (TKNO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TKNO's current score at https://13fpro.ai/research/TKNO (free sign-up required for the full ranking).

Which hedge funds own the most TKNO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TKNO include Roubaix Capital,, ROYCE & ASSOCIATES, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TKNO as soon as new 13F filings post.

Where does 13F Pro source TKNO data?

All Alpha Teknova, Inc. fundamentals and ownership data come directly from SEC EDGAR. Alpha Teknova, Inc. files with the SEC under CIK 1850902. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TKNO in?

Alpha Teknova, Inc. (TKNO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TKNO research updated on 13F Pro?

TKNO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Alpha Teknova, Inc.(TKNO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1850902 TKNO stock profile & AI dashboard →

13F Pro Quality Score

23.0/100

Rank #2,627 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

49.0/100

Profitability

12.5/100

Balance Sheet

13.1/100

Earnings Quality

30.0/100

Free Cash Flow

11.5/100

Institutional Flow

63.1/100

Revenue Scale

9.6/100

Dilution Risk

18.9/100

TKNO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Alpha Teknova, Inc. (TKNO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TKNO at 23.0/100 on a 32-signal composite quality model, placing it at rank #2,627 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (9.6) and free cash flow (11.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Alpha Teknova, Inc. reports quarterly revenue of $11.1M, net income of $-4.6M, an operating margin of -38.8%. Top institutional holders of TKNO by reported 13-F value include Roubaix Capital,, ROYCE & ASSOCIATES, BlackRock,, based on the most recent SEC filings. TKNO trades on the Nasdaq exchange and files with the SEC under CIK 1850902. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TKNO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alpha Teknova, Inc. directly from SEC EDGAR. Alpha Teknova, Inc.'s 13F Pro composite quality score has ranged between 12 and 35 since 2022, currently 23.0 — a declining long-term trajectory across 24 quarterly and live scoring snapshots.

✦

Fun facts about Alpha Teknova, Inc.

Quirks, history, and lore behind TKNO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. life sciences company · small-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
Annual revenue in the range of tens of millions of dollars, serving a niche but critical corner of the biopharma supply chain — small by Wall Street standards, indispensable to its customers.
3
The History
Founded in the 1990s, it spent decades as a quiet behind-the-scenes supplier before going public on Nasdaq in 2021, right as demand for its products was surging.
4
The Secret
It doesn't make drugs — it makes the buffers, reagents, and culture media that biopharmaceutical labs need to develop and manufacture drugs; if you run a cell therapy program, you probably use its products.
5
The Lore
Its facility in Hollister, California — a small agricultural town — is essentially a custom recipe shop for scientists, producing made-to-order biological solutions at scale.
6
The Giveaway
The ticker spells out its mission pretty clearly: TKNO, short for a name blending "alpha" (the Greek symbol of excellence) with "teknova" — a biopharma reagent and buffer maker that keeps the world's drug labs stocked.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$11.1M

Net Income

Q1 2026

$-4.6M

Free Cash Flow

Q1 2026

$-3.6M

Operating Margin

Q1 2026

-38.8%

D/E Ratio

Q1 2026

0.20

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+2.9% YoY

$37.7MFY 2024

FY21 $36.9MFY22 $41.4MFY23 $36.7MFY24 $37.7M

Net Income

+27.3% YoY

$-26.7MFY 2024

FY21 $-9.8MFY22 $-47.5MFY23 $-36.8MFY24 $-26.7M

Operating Income

+26.5% YoY

$-26.1MFY 2024

FY21 $-12.0MFY22 $-49.7MFY23 $-35.6MFY24 $-26.1M

EPS (Diluted)

+50.9% YoY

$-0.57FY 2024

FY21 $-0.61FY22 $-1.69FY23 $-1.16FY24 $-0.57

Total Assets

-7.6% YoY

$118.8MFY 2024

FY21 $166.5MFY22 $152.3MFY23 $128.6MFY24 $118.8M

Total Debt

+1.8% YoY

$13.5MFY 2024

FY21 $11.9MFY22 $22.0MFY23 $13.3MFY24 $13.5M

Op. Cash Flow

+34.1% YoY

$-12.4MFY 2024

FY21 $-9.1MFY22 $-27.4MFY23 $-18.8MFY24 $-12.4M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$37.7M +2.9%	$36.7M -11.4%	$41.4M +12.3%	$36.9M +17.9%	$31.3M	—
Net Income	$-26.7M +27.3%	$-36.8M +22.5%	$-47.5M -384.2%	$-9.8M -374.6%	$3.6M	—
Operating Income	$-26.1M +26.5%	$-35.6M +28.4%	$-49.7M -313.5%	$-12.0M -357.5%	$4.7M	—
EPS (Diluted)	$-0.57 +50.9%	$-1.16 +31.4%	$-1.69 -177.0%	$-0.61 -814.3%	$0.09	—
Total Assets	$118.8M -7.6%	$128.6M -15.5%	$152.3M -8.6%	$166.5M +164.7%	$62.9M	—
Total Debt	$13.5M +1.8%	$13.3M -39.7%	$22.0M +85.1%	$11.9M	$0.00	—
Operating Cash Flow	$-12.4M +34.1%	$-18.8M +31.3%	$-27.4M -202.1%	$-9.1M -462.0%	$2.5M	—

AI Insight: TKNO Financial Trends

Alpha Teknova shows modest revenue growth to $11M in Q1 2026 but equity base has eroded 18% over two years amid persistent losses.

• Revenue increased from $10M in Q2 2024 to $11M in Q1 2026, showing gradual improvement.

• Operating losses narrowed from $-5M in Q2 2024 to $-4M in Q1 2026.

• Equity declined steadily from $79M in Q2 2024 to $65M in Q1 2026.

• Operating cash flow improved from $-3M in Q2 2024 to breakeven in Q4 2025.

⚠ Operating cash flow deteriorated to $-3M in Q1 2026 after reaching breakeven in Q4 2025.

⚠ Debt remains flat at $13M while equity base continues shrinking, worsening leverage profile.

AI Insight: TKNO Ratio Trends

Alpha Teknova showed meaningful margin improvement through mid-2025 before deteriorating again, with operating margin improving from -77.6% in Q3 2024 to -32.9% in Q2 2025.

• Operating margin improved dramatically from -77.6% in Q3 2024 to -32.9% in Q2 2025, marking significant operational progress.

• ROE improved from -34.7% in Q3 2024 to -18.8% in Q2 2025, indicating better equity returns during recovery period.

• Operating margin deteriorated from -32.9% in Q2 2025 to -38.8% in Q1 2026, reversing previous gains.

⚠ Debt-to-equity ratio has steadily increased from 0.15 in Q3 2024 to 0.20 in Q1 2026.

⚠ Company remains deeply unprofitable with all profitability metrics still negative despite recent improvements.

Get alerted when TKNO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Alpha Teknova, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TKNO

Roubaix Capital, LLC
$5.4M1,882,355 sh
ROYCE & ASSOCIATES LP
$3.1M1,069,162 sh
BlackRock, Inc.
$2.1M716,774 sh
MILLENNIUM MANAGEMENT LLC
$1.3M447,138 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.3M441,879 sh
UBS Group AG
$939.7K325,163 sh
Conestoga Capital Advisors, LLC
$916.4K317,084 sh
GEODE CAPITAL MANAGEMENT, LLC
$890.0K307,873 sh
BANK OF AMERICA CORP /DE/
$659.7K228,286 sh
Massar Capital Management, LP
$578.0K200,000 sh

Fund	Value	Shares
Roubaix Capital, LLC	$5.4M	1,882,355
ROYCE & ASSOCIATES LP	$3.1M	1,069,162
BlackRock, Inc.	$2.1M	716,774
MILLENNIUM MANAGEMENT LLC	$1.3M	447,138
VANGUARD CAPITAL MANAGEMENT LLC	$1.3M	441,879
UBS Group AG	$939.7K	325,163
Conestoga Capital Advisors, LLC	$916.4K	317,084
GEODE CAPITAL MANAGEMENT, LLC	$890.0K	307,873
BANK OF AMERICA CORP /DE/	$659.7K	228,286
Massar Capital Management, LP	$578.0K	200,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TKNO on your watchlist

Track score changes the day Alpha Teknova, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TKNO a good stock to buy?

13F Pro's AI-powered analysis of Alpha Teknova, Inc. (TKNO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TKNO are available on the TKNO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TKNO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TKNO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Alpha Teknova, Inc.'s investment landscape.